Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Kadimastem ( (IL:KDST) ) is now available.
Kadimastem Ltd has announced a significant licensing agreement with NLS Pharmaceuticals Ltd. This deal is expected to impact Kadimastem’s business activities, potentially aiding in capital raising efforts and enhancing their market positioning.
More about Kadimastem
YTD Price Performance: 48.62%
Average Trading Volume: 15,684
Current Market Cap: ILS74.9M
See more insights into KDST stock on TipRanks’ Stock Analysis page.